Shionogi files metreleptin in Japan on back of rare investigator-initiated trial
This article was originally published in Scrip
Shionogi's recent submission for the approval of Amylin's metreleptin in Japan follows a rarely used local procedure for the clinical development of high-need drugs for niche indications.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.